<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">OTO</journal-id>
<journal-id journal-id-type="hwp">spoto</journal-id>
<journal-title>Otolaryngology–Head and Neck Surgery</journal-title>
<issn pub-type="ppub">0194-5998</issn>
<issn pub-type="epub">1097-6817</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0194599812442490</article-id>
<article-id pub-id-type="publisher-id">10.1177_0194599812442490</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Head and Neck Surgery</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Integrative Analysis in Oral Squamous Cell Carcinoma Reveals DNA Copy Number–Associated miRNAs Dysregulating Target Genes</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Serrano</surname><given-names>Nicholas A.</given-names></name>
<xref ref-type="aff" rid="aff1-0194599812442490">1</xref>
<xref ref-type="aff" rid="aff2-0194599812442490">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Xu</surname><given-names>Chang</given-names></name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="aff1-0194599812442490">1</xref>
<xref ref-type="aff" rid="aff3-0194599812442490">3</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Liu</surname><given-names>Yan</given-names></name>
<degrees>MS</degrees>
<xref ref-type="aff" rid="aff4-0194599812442490">4</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Wang</surname><given-names>Pei</given-names></name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="aff4-0194599812442490">4</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Fan</surname><given-names>Wenhong</given-names></name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="aff4-0194599812442490">4</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Upton</surname><given-names>Melissa P.</given-names></name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff5-0194599812442490">5</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Houck</surname><given-names>John R.</given-names></name>
<xref ref-type="aff" rid="aff6-0194599812442490">6</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Lohavanichbutr</surname><given-names>Pawadee</given-names></name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff6-0194599812442490">6</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Kao</surname><given-names>Michael</given-names></name>
<xref ref-type="aff" rid="aff1-0194599812442490">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Zhao</surname><given-names>Lue Ping</given-names></name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="aff4-0194599812442490">4</xref>
<xref ref-type="aff" rid="aff7-0194599812442490">7</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Schwartz</surname><given-names>Stephen M.</given-names></name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="aff6-0194599812442490">6</xref>
<xref ref-type="aff" rid="aff8-0194599812442490">8</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Chen</surname><given-names>Chu</given-names></name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="aff1-0194599812442490">1</xref>
<xref ref-type="aff" rid="aff6-0194599812442490">6</xref>
<xref ref-type="aff" rid="aff8-0194599812442490">8</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Méndez</surname><given-names>Eduardo</given-names></name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-0194599812442490">1</xref>
<xref ref-type="aff" rid="aff3-0194599812442490">3</xref>
<xref ref-type="aff" rid="aff9-0194599812442490">9</xref>
</contrib>
</contrib-group>
<aff id="aff1-0194599812442490"><label>1</label>Department of Otolaryngology–Head and Neck Surgery, University of Washington, Seattle, Washington, USA</aff>
<aff id="aff2-0194599812442490"><label>2</label>University of Washington, School of Medicine, Seattle, Washington, USA</aff>
<aff id="aff3-0194599812442490"><label>3</label>Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA</aff>
<aff id="aff4-0194599812442490"><label>4</label>Program in Biostatistics &amp; Biomathematics, Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA</aff>
<aff id="aff5-0194599812442490"><label>5</label>Department of Pathology, University of Washington, Seattle, Washington, USA</aff>
<aff id="aff6-0194599812442490"><label>6</label>Program in Epidemiology, Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA</aff>
<aff id="aff7-0194599812442490"><label>7</label>Department of Biostatistics, University of Washington, Seattle, Washington, USA</aff>
<aff id="aff8-0194599812442490"><label>8</label>Department of Epidemiology, University of Washington, Seattle, Washington, USA</aff>
<aff id="aff9-0194599812442490"><label>9</label>Surgery and Perioperative Care Service, VA Puget Sound Health Care System, Seattle, Washington, USA</aff>
<author-notes>
<corresp id="corresp1-0194599812442490">Eduardo Méndez, MD, Department of Otolaryngology–Head and Neck Surgery, University of Washington, Clinical Research Division, Fred Hutchinson Cancer Research Center, Surgery and Perioperative Care Service, VA Puget Sound Health Care System, 6507, 52nd Ave NE, Seattle, WA 98115-7744 Email: <email>edmendez@u.washington.edu</email>
</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>9</month>
<year>2012</year>
</pub-date>
<volume>147</volume>
<issue>3</issue>
<fpage>501</fpage>
<lpage>508</lpage>
<history>
<date date-type="received">
<day>31</day>
<month>10</month>
<year>2011</year>
</date>
<date date-type="rev-recd">
<day>1</day>
<month>2</month>
<year>2012</year>
</date>
<date date-type="accepted">
<day>27</day>
<month>2</month>
<year>2012</year>
</date>
</history>
<permissions>
<copyright-statement>© American Academy of Otolaryngology—Head and Neck Surgery Foundation 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="society">Official journal of the American Academy of Otolaryngology–Head and Neck Surgery Foundation</copyright-holder>
</permissions>
<abstract>
<sec id="section1-0194599812442490">
<title>Objective</title>
<p>To better understand possible mechanisms involved in the dysregulation of gene expression unique to oral squamous cell carcinoma (OSCC) metastasis, the investigators examined the differential expression of microRNAs (miRNAs) in OSCC metastasis and their functional impact on target gene expression.</p>
</sec>
<sec id="section2-0194599812442490">
<title>Study Design</title>
<p>Observational assessment of DNA copy number, miRNA, and RNA expression in primary and metastatic OSCC.</p>
</sec>
<sec id="section3-0194599812442490">
<title>Setting</title>
<p>University of Washington Medical Center and affiliated hospitals.</p>
</sec>
<sec id="section4-0194599812442490">
<title>Subjects</title>
<p>Tumor samples were taken from patients with primary incident OSCC; cells were laser-capture microdissected from 17 nonmetastatic primary tumors and 20 metastatic lymph nodes.</p>
</sec>
<sec id="section5-0194599812442490">
<title>Methods</title>
<p>DNA copy number aberrations and gene expression profiles were previously determined using Affymetrix 250K <italic>Nsp</italic> I SNP arrays and HU133 plus 2.0 expression arrays. miRNAs were interrogated with Exiqon’s Ready-to-Use PCR Panels assessing the expression of 368 human miRNAs.</p>
</sec>
<sec id="section6-0194599812442490">
<title>Results</title>
<p>Investigators found 31 miRNAs differentially expressed between metastatic and nonmetastatic samples (false discovery rate &lt;0.4; 26 overexpressed and 5 underexpressed in metastatic samples). Expression of 7 of these miRNAs was significantly associated with their DNA copy numbers, and expressions of 8 of these miRNAs were significantly associated with their target genes. Among these unique miRNAs, miR-140-3p, miR-29c, and miR-29a were differentially expressed in metastasis versus nonmetastatic samples and had a strong positive correlation with their DNA copy numbers and a negative correlation with the expression of their target genes.</p>
</sec>
<sec id="section7-0194599812442490">
<title>Conclusion</title>
<p>Results suggest that DNA copy number aberration may play a role in the dysregulation of some differentially expressed miRNAs in OSCC metastasis, warranting further investigation.</p>
</sec>
</abstract>
<kwd-group>
<kwd>oral squamous cell carcinoma</kwd>
<kwd>microRNA</kwd>
<kwd>head and neck cancer</kwd>
<kwd>miRNA-140-3p</kwd>
<kwd>miRNA-29a</kwd>
<kwd>miRNA-29c</kwd>
<kwd>metastases</kwd>
<kwd>oral cancer metastases</kwd>
<kwd>DNA copy number</kwd>
<kwd>miRNA profiling</kwd>
<kwd>integrative analysis</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<p>Oral squamous cell carcinoma (OSCC) is one of the most common cancer types worldwide. Despite considerable advances in surgical techniques and the use of adjuvant treatment modalities, the overall prognosis for oral squamous cell carcinoma (OSCC) has not improved significantly in the past 2 decades.<sup><xref ref-type="bibr" rid="bibr1-0194599812442490">1</xref>,<xref ref-type="bibr" rid="bibr2-0194599812442490">2</xref></sup> In particular, the presence of lymph node involvement is associated with a 50% decrease in 5-year survival.<sup><xref ref-type="bibr" rid="bibr3-0194599812442490">3</xref></sup> Therefore, it is critical to gain a better understanding of the molecular mechanisms that drive metastasis in OSCC.</p>
<p>The use of high-throughput DNA microarrays to detect genome-wide DNA copy number changes (genomics) and the gene expression levels (transcriptomics) holds much promise in achieving this goal. We previously mapped DNA copy number aberrations in laser-dissected tumor cells from lymph node metastases and showed (1) that there were strong associations of DNA copy number with gene expression and (2) that the combination of DNA copy number and differential gene expression data was effective at identifying candidate transcripts that appear to have better predictive capacity for prognosis than stage alone.<sup><xref ref-type="bibr" rid="bibr4-0194599812442490">4</xref></sup> However, we still need better understanding of other mechanisms associated with aberrant gene expression in metastasis in order to identify dysregulated pathways associated with prognosis and might be relevant for the development of new therapies. There is now emerging evidence that microRNAs (miRNAs) may play a role in cancer and that dysregulation of miRNA expression is important in head and neck cancer.<sup><xref ref-type="bibr" rid="bibr5-0194599812442490">5</xref>,<xref ref-type="bibr" rid="bibr6-0194599812442490">6</xref></sup> Mature miRNAs have the ability to negatively regulate protein expression at the posttranscriptional level through direct binding to the 3′ untranslated region (UTR) of specific messenger RNA (mRNA).<sup><xref ref-type="bibr" rid="bibr7-0194599812442490">7</xref>,<xref ref-type="bibr" rid="bibr8-0194599812442490">8</xref></sup> These miRNA negatively affect the translation of the mRNA strand by either blocking target gene expression or cleaving the mRNA when the complementarity is perfect or nearly so.<sup><xref ref-type="bibr" rid="bibr9-0194599812442490">9</xref></sup> We hypothesize that these molecular properties of miRNAs can help to better explain, at least in part, aberrant gene expression in metastatic OSCC cells.</p>
<p>By determining miRNA profiles on samples for which we had previously obtained genome-wide DNA copy number and gene expression profiles,<sup><xref ref-type="bibr" rid="bibr4-0194599812442490">4</xref></sup> we set out to explore the differences in miRNA levels between tumor cells from metastases in lymph nodes versus tumor cells from nonmetastatic primary OSCC tumors. We also aimed to determine the impact of dysregulation of miRNAs on the expression of their target genes. Given that our prior results had shown a significant correlation between DNA copy number aberrations and gene expression,<sup><xref ref-type="bibr" rid="bibr4-0194599812442490">4</xref></sup> we also sought to determine whether DNA copy number aberrations could exert similar influences on miRNA dysregulation.</p>
<sec id="section8-0194599812442490" sec-type="materials|methods">
<title>Materials and Methods</title>
<sec id="section9-0194599812442490">
<title>Patient Samples</title>
<p>Patients with primary incident OSCC were enrolled with institutional review board approval from 3 collaborating institutions: University of Washington Medical Center, Harborview Medical Center, and Puget Sound Veterans Affairs Health Care System. Blood was collected at time of enrollment. During surgery, we collected primary carcinomas as well as lymph nodes from patients with known metastatic OSCC. All surgeries were conducted at the University of Washington Medical Center and affiliated hospitals.</p>
</sec>
<sec id="section10-0194599812442490">
<title>Sample Preparation</title>
<p>Tissue samples were flash frozen in the operating room immediately after tumor resection and stored in liquid nitrogen until use. The samples were thawed to –20°C and embedded in OCT, and 8-µm-thick frozen sections were cut on RNase-free slides and stained at the Fred Hutchinson Cancer Research Center, Seattle, Washington. One in every 8 consecutive slides was stained with hematoxylin and eosin for pathologic analysis. Additionally, a 20-µm-thick frozen section was cut to determine the quality of nucleic acids within the embedded tumor. Tumor cells were isolated using laser capture microdissection, and the DNA and RNA were extracted as described in Xu et al.<sup><xref ref-type="bibr" rid="bibr10-0194599812442490">10</xref></sup> We isolated miRNA from the total RNA using the RNeasy Micro Kit as per manufacturer’s protocol (Qiagen, Valencia, California).</p>
</sec>
<sec id="section11-0194599812442490">
<title>Real-Time Quantification of miRNAs</title>
<p>We evaluated miRNA profiles of 20 metastatic OSCC in lymph nodes and 17 nonmetastatic primary tumors using miRCURY LNA Universal RT microRNA Ready-to-Use PCR Panels (Exiqon, Vedbaek, Denmark). As described in the product manual (<ext-link ext-link-type="uri" xlink:href="http://www.exiqon.com">www.exiqon.com</ext-link>), miRNA samples were first reverse transcribed. The complementary DNA was then used to conduct real-time polymerase chain reaction (PCR) using the Ready-to-Use Panel (comprising 368 LNA-modified probes for human miRNAs in the miRBase microRNA Registry v13.0) on an ABI 7900HT Fast Real-Time PCR System.</p>
</sec>
<sec id="section12-0194599812442490">
<title>Data Preprocessing</title>
<p>Samples with undetectable miRNA expression were given a cycle threshold (Ct) value of 40. We normalized the plates using an interplate calibrator that was present on each array in triplicate, per the manufacturer’s instructions (Exiqon). Ct values from samples with miRNA expression that were greater than 36 were assigned a value of 36. Additionally, as outlined in Hui et al,<sup><xref ref-type="bibr" rid="bibr11-0194599812442490">11</xref></sup> target miRNAs with a Ct value greater than 36 in 80% of the metastatic lymph node samples or 80% of the nonmetastatic primary tumor samples were removed from the analysis. The mean of 3 controls that were provided on the miRNA array (U6, SNORD38B, and SNORD49A) was used as the endogenous control reference gene.</p>
</sec>
<sec id="section13-0194599812442490">
<title>Statistical Analysis</title>
<sec id="section14-0194599812442490">
<title>MicroRNA differential expression analysis</title>
<p>We determined the differential expression values using the ΔΔCt method of Pfaffl<sup><xref ref-type="bibr" rid="bibr12-0194599812442490">12</xref></sup> with a PCR amplification efficiency of E = 2. We first calibrated the Ct values using the interplate calibrator UniSp3 to normalize the Ct values from different plates. Undetermined values were given a Ct value of 36. We excluded the miRNAs if 80% of the samples had a Ct of 36 in either metastatic or nonmetastatic subgroups. The control Ct value was subtracted from each Ct data point on that plate to generate the ΔCt values, which were examined using the Wilcoxon rank sum test, with the Benjamini-Hochberg adjustment for false discovery rate (FDR),<sup><xref ref-type="bibr" rid="bibr13-0194599812442490">13</xref></sup> as outlined by Hui et al.<sup><xref ref-type="bibr" rid="bibr11-0194599812442490">11</xref></sup></p>
</sec>
<sec id="section15-0194599812442490">
<title>DNA copy number estimation and gene expression profiling</title>
<p>The DNA and RNA of the laser-dissected tumor cells for each of the 20 lymph node metastatic samples were hybridized onto Affymetrix Human Mapping 250K <italic>Nsp</italic> I SNP and Affymetrix Human Genome U133 Plus 2.0 arrays, respectively, as described previously.<sup><xref ref-type="bibr" rid="bibr4-0194599812442490">4</xref></sup> We combined this previous analysis with an analysis of 17 nonmetastatic primary tumor samples, which were processed and interrogated similarly.</p>
</sec>
<sec id="section16-0194599812442490">
<title>Association between DNA copy numbers and miRNA levels</title>
<p>We obtained the genome sequences and chromosomal coordinates of all expressed miRNAs using the miRBase V 14.0 (<ext-link ext-link-type="uri" xlink:href="http://www.mirbase.org">http://www.mirbase.org</ext-link>;<sup><xref ref-type="bibr" rid="bibr14-0194599812442490">14</xref><xref ref-type="bibr" rid="bibr15-0194599812442490"/><xref ref-type="bibr" rid="bibr16-0194599812442490"/>-<xref ref-type="bibr" rid="bibr17-0194599812442490">17</xref></sup> hosted by the Faculty of Life Sciences, University of Manchester). The DNA copy number of each miRNA was determined by averaging the estimated DNA copy number probes<sup><xref ref-type="bibr" rid="bibr4-0194599812442490">4</xref></sup> on the DNA copy number arrays falling into a neighborhood of 250 Kb upstream and downstream of each miRNA location on the genome. We then used linear regression models to assess the association between miRNA transcript levels and their DNA copy number alterations. The <italic>P</italic> value was recorded for the predictive significance of DNA copy number in each regression model.</p>
</sec>
<sec id="section17-0194599812442490">
<title>Association between gene expressions, DNA copy number, and miRNA</title>
<p>To investigate the impact of miRNA on gene expression, we considered that each gene expression level could be influenced by both DNA copy number (as detailed in Xu et al<sup><xref ref-type="bibr" rid="bibr4-0194599812442490">4</xref></sup>) and miRNA levels. Thus, when assessing the influence of miRNA on gene expression, we also included terms for the DNA copy number of each particular gene as described by Xu et al. We analyzed the potential target genes of all expressed miRNAs using the TargetScanHuman version 5.1. A full explanation of the algorithm used to obtain the context score can be found at <ext-link ext-link-type="uri" xlink:href="http://www.targetscan.org/">http://www.targetscan.org/</ext-link>. This analysis yielded all potential gene targets for the expressed miRNAs. For each transcript, we only considered the top 3 miRNAs receiving the highest complementarity scores from TargetScanHuman. We then fitted linear regression models by treating each transcript level as the response variable, with the DNA copy number at its corresponding location, as well as the abundance levels of the top 3 matching miRNAs serving as the predictor variables. The coefficients in front of the miRNA abundances together with their <italic>P</italic> values were recorded.</p>
</sec>
<sec id="section18-0194599812442490">
<title>Ingenuity pathways analysis</title>
<p>Among the predicted targets of miR-140-3p and miR-29a, we further studied the subset that was associated with DNA copy number aberrations, that showed significant expression difference (<italic>P</italic> &lt; .01) in the metastatic samples, and that had a negative impact on their target genes. This subset was analyzed using Ingenuity Pathway Analysis software (IPA, version 8.5, Ingenuity Systems, Redwood City, California; <ext-link ext-link-type="uri" xlink:href="http://www.ingenuity.com">http://www.ingenuity.com</ext-link> Core Analysis). The Functions/Pathways/Tox list Analyses were performed with Ingenuity Knowledge Base (Genes Only) as reference set, and both direct and indirect relationships were considered in the network analysis.</p>
</sec>
</sec>
</sec>
<sec id="section19-0194599812442490" sec-type="results">
<title>Results</title>
<sec id="section20-0194599812442490">
<title>Study Population</title>
<p>Selected characteristics of the study participants are shown in supplementary information, Table S1 (available at <ext-link ext-link-type="uri" xlink:href="http://otojournal.org">otojournal.org</ext-link>). Of the 20 OSCC patients with lymph node metastases, 8 had cancers arising in the oropharynx, whereas the remaining carcinomas arose from the oral cavity. The majority of patients had N2 or greater nodal staging (ie, multiple metastatic nodes detected). The age range of the patients with metastases was 23 to 84 years (mean, 56.8 years). Of the 17 patients with nonmetastatic primary OSCC, 3 primary tumors arose in the oropharynx, and the remaining tumors were from the oral cavity. Eight of these patients with nonmetastatic primary OSCC had American Joint Committee on Cancer (AJCC) stage I tumors, and 9 had AJCC stage II tumors. The age range of patients without metastases was 47 to 79 years (mean, 59.2 years). The follow-up interval for the patients with nonmetastatic primaries was 2.7 years (range, 0.5-5.4 years).</p>
</sec>
<sec id="section21-0194599812442490">
<title>Differential Expression Analysis</title>
<p>Of the 368 miRNAs on the assay platform, only 155 were expressed in either 80% of nonmetastatic tumor cells or 80% of the metastatic tumor cells. Of these 155 miRNAs, 31 miRNAs were differentially expressed in metastatic compared with nonmetastatic tumor cells (FDR ≤ 0.4) (<xref ref-type="table" rid="table1-0194599812442490"><bold>Table 1</bold></xref>). Of these, 26 were overexpressed in the lymph node metastases, and 5 were underexpressed (<xref ref-type="table" rid="table1-0194599812442490"><bold>Table 1</bold></xref>).</p>
<table-wrap id="table1-0194599812442490" position="float">
<label>Table 1.</label>
<caption>
<p>List of 31 MicroRNAs Differentially Expressed between Metastatic and Nonmetastatic Oral Squamous Cell Carcinoma</p>
</caption>
<graphic alternate-form-of="table1-0194599812442490" xlink:href="10.1177_0194599812442490-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left">MicroRNA</th>
<th align="center">False Discovery Rate</th>
<th align="center">Raw (Unadjusted) <italic>P</italic> Value</th>
<th align="center"><italic>Z</italic> Score</th>
</tr>
</thead>
<tbody>
<tr>
<td>Up-regulated</td>
<td/>
<td/>
<td/>
</tr>
<tr>
<td> hsa-miR-150</td>
<td>0.0016</td>
<td>&lt;.0001</td>
<td>4.4041</td>
</tr>
<tr>
<td> hsa-miR-155</td>
<td>0.0054</td>
<td>.0001</td>
<td>3.9774</td>
</tr>
<tr>
<td> hsa-let-7g</td>
<td>0.0132</td>
<td>.0003</td>
<td>3.5812</td>
</tr>
<tr>
<td> hsa-miR-195</td>
<td>0.0133</td>
<td>.0003</td>
<td>3.6116</td>
</tr>
<tr>
<td> hsa-miR-142-3p</td>
<td>0.0363</td>
<td>.0012</td>
<td>3.2459</td>
</tr>
<tr>
<td> hsa-miR-342-3p</td>
<td>0.0901</td>
<td>.0048</td>
<td>2.8192</td>
</tr>
<tr>
<td> hsa-miR-140-3p</td>
<td>0.0901</td>
<td>.0040</td>
<td>2.8802</td>
</tr>
<tr>
<td> hsa-miR-497</td>
<td>0.0901</td>
<td>.0058</td>
<td>2.7583</td>
</tr>
<tr>
<td> hsa-miR-146b-5p</td>
<td>0.0901</td>
<td>.0058</td>
<td>2.7583</td>
</tr>
<tr>
<td> hsa-miR-218</td>
<td>0.0901</td>
<td>.0058</td>
<td>2.7583</td>
</tr>
<tr>
<td> hsa-miR-29c</td>
<td>0.1181</td>
<td>.0084</td>
<td>2.6363</td>
</tr>
<tr>
<td> hsa-miR-146a</td>
<td>0.1293</td>
<td>.0100</td>
<td>2.5754</td>
</tr>
<tr>
<td> hsa-miR-29a</td>
<td>0.1549</td>
<td>.0130</td>
<td>2.4839</td>
</tr>
<tr>
<td> hsa-miR-26b</td>
<td>0.1566</td>
<td>.0142</td>
<td>2.4535</td>
</tr>
<tr>
<td> hsa-miR-145</td>
<td>0.1591</td>
<td>.0154</td>
<td>2.4230</td>
</tr>
<tr>
<td> hsa-let-7f</td>
<td>0.3388</td>
<td>.0397</td>
<td>2.0573</td>
</tr>
<tr>
<td> hsa-miR-34a</td>
<td>0.3388</td>
<td>.0459</td>
<td>1.9963</td>
</tr>
<tr>
<td> hsa-miR-148a</td>
<td>0.3388</td>
<td>.0459</td>
<td>1.9963</td>
</tr>
<tr>
<td> hsa-miR-100</td>
<td>0.3388</td>
<td>.0459</td>
<td>1.9963</td>
</tr>
<tr>
<td> hsa-miR-10a</td>
<td>0.3420</td>
<td>.0529</td>
<td>1.9353</td>
</tr>
<tr>
<td> hsa-miR-29b</td>
<td>0.3420</td>
<td>.0529</td>
<td>1.9353</td>
</tr>
<tr>
<td> hsa-miR-15a</td>
<td>0.3729</td>
<td>.0652</td>
<td>1.8439</td>
</tr>
<tr>
<td> hsa-miR-125b</td>
<td>0.3729</td>
<td>.0609</td>
<td>1.8744</td>
</tr>
<tr>
<td> hsa-miR-192</td>
<td>0.3729</td>
<td>.0698</td>
<td>1.8134</td>
</tr>
<tr>
<td> hsa-miR-199a-3p</td>
<td>0.3729</td>
<td>.0652</td>
<td>1.8439</td>
</tr>
<tr>
<td> hsa-miR-26a</td>
<td>0.3730</td>
<td>.0746</td>
<td>1.7830</td>
</tr>
<tr>
<td>Down-regulated</td>
<td/>
<td/>
<td/>
</tr>
<tr>
<td> hsa-miR-34c-5p</td>
<td>0.1621</td>
<td>.0167</td>
<td>–2.3925</td>
</tr>
<tr>
<td> hsa-miR-92b</td>
<td>0.3388</td>
<td>.0427</td>
<td>–2.0268</td>
</tr>
<tr>
<td> hsa-miR-23b</td>
<td>0.3420</td>
<td>.0529</td>
<td>–1.9353</td>
</tr>
<tr>
<td> hsa-miR-149</td>
<td>0.3729</td>
<td>.0698</td>
<td>–1.8134</td>
</tr>
<tr>
<td> hsa-miR-95</td>
<td>0.3730</td>
<td>.0746</td>
<td>–1.7830</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
<sec id="section22-0194599812442490">
<title>DNA Copy Number Integration Analysis</title>
<p>To evaluate genomic influences that may drive miRNA expression, we looked at the association of DNA copy number on the expression of our 155 target miRNAs. The results are shown in <xref ref-type="fig" rid="fig1-0194599812442490"><bold>Figure 1</bold></xref>. We found that 11 of our 155 miRNAs showed a significant association with DNA copy number (<xref ref-type="table" rid="table2-0194599812442490"><bold>Table 2</bold></xref>). Of these 11, 7 miRNAs were differentially expressed: miR-29a, miR-29c, miR-140-3p, miR-34c-5p, miR-10a, miR-149, and miR-192 (<xref ref-type="fig" rid="fig2-0194599812442490"><bold>Figure 2A</bold></xref>).</p>
<table-wrap id="table2-0194599812442490" position="float">
<label>Table 2.</label>
<caption>
<p>DNA Copy Number–Associated MicroRNAs (miRNAs) Differentially Expressed in Oral Squamous Cell Carcinoma Metastasis</p>
</caption>
<graphic alternate-form-of="table2-0194599812442490" xlink:href="10.1177_0194599812442490-table2.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left">DNA Copy Number–Associated miRNAs</th>
<th align="center"><italic>P</italic> Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>miR-140-3p</td>
<td>.0010</td>
</tr>
<tr>
<td>miR-29c</td>
<td>.0429</td>
</tr>
<tr>
<td>miR-29a</td>
<td>.0119</td>
</tr>
<tr>
<td>miR-34c-5p</td>
<td>.0028</td>
</tr>
<tr>
<td>miR-10a</td>
<td>.0144</td>
</tr>
<tr>
<td>miR-149</td>
<td>.0321</td>
</tr>
<tr>
<td>miR-192</td>
<td>.0002</td>
</tr>
</tbody>
</table>
</table-wrap>
<fig id="fig1-0194599812442490" position="float">
<label>Figure 1.</label>
<caption>
<p>Manhattan plot. Line indicates the Bonferroni <italic>P</italic> value cutoff for DNA copy number–associated microRNAs. Black dots indicate miRNAs that are negatively associated with gene expression.</p>
</caption>
<graphic xlink:href="10.1177_0194599812442490-fig1.tif"/>
</fig>
<fig id="fig2-0194599812442490" position="float">
<label>Figure 2.</label>
<caption>
<p>Schematic of study workflow. (A) DNA copy number–associated miRNAs. (B) Gene expression–associated miRNAs. Three miRNAs are differentially expressed oral squamous cell carcinoma metastasis, are associated with their DNA copy number, and have a negative impact on their target gene expression.</p>
</caption>
<graphic xlink:href="10.1177_0194599812442490-fig2.tif"/>
</fig>
</sec>
<sec id="section23-0194599812442490">
<title>Target Gene Analysis</title>
<p>Based on our <italic>in silico</italic> analysis with TargetScanHuman, we found 47,385 potential gene targets corresponding to the genome sequences of the 155 expressed miRNAs. The distribution of the coefficients describing the association between the 155 miRNAs and the expression of their target genes is shown in Supplemental Figure S1. This plot reveals a normal distribution around zero, indicating that there was not a general preponderance for negative correlations between miRNAs and their target genes. Given that miRNAs are known to silence gene expression, we chose to focus on miRNAs that had significant negative associations (<italic>P</italic> &lt; .01, coefficient &lt;0) with multiple (at least 5) transcripts. There were 23 miRNA satisfying this selection criterion, which are shown in <xref ref-type="fig" rid="fig3-0194599812442490"><bold>Figure 3</bold></xref>. Of these 23 miRNAs, we found that 8 miRNAs were also among those found to be differentially expressed in metastatic tumor cells: miR-155, miR-142-3p, miR-29a, miR-29c, miR-140-3p, miR-148a, miR-23b, and miR-15a (<xref ref-type="fig" rid="fig2-0194599812442490"><bold>Figure 2B</bold></xref> and Table S2). Lastly, the intersection from the above analyses showed that miR-29a (7q32.2), miR-29c (1q32.2), and miR-140-3p (16q22.1) not only were differentially expressed in metastasis but also had a strong positive correlation with their DNA copy numbers and a negative correlation with their target genes (<xref ref-type="fig" rid="fig2-0194599812442490"><bold>Figure 2</bold></xref>).</p>
<fig id="fig3-0194599812442490" position="float">
<label>Figure 3.</label>
<caption>
<p>Manhattan plot. Black dots indicate the 23 microRNAs (miRNAs) that are negatively associated with gene expression. The 8 labeled miRNAs are those that are differentially expressed in oral squamous cell carcinoma metastasis.</p>
</caption>
<graphic xlink:href="10.1177_0194599812442490-fig3.tif"/>
</fig>
</sec>
<sec id="section24-0194599812442490">
<title>Functional Network Analysis of miR-29a, miR-29c, and miR-140-3p Target Genes</title>
<p>To explore the pathways and regulatory elements most likely associated with the changes induced by the miR-29 family and miR-140-3p, we performed Ingenuity Pathway Analysis on the expression of the target genes that were correlated with miRNA expression in metastatic samples (<italic>P</italic> &lt; .01). The top networks generated by targets of miR-29a/c and miR-140-3p are shown in Supplemental Figures S2 and S3, respectively. For miRNA-29, pathway analysis revealed a network associated with organismal injury, dermatological diseases, and conditions. The network identified <italic>ITGB1, PI3K</italic>, and <italic>NF-KB</italic> as central regulators. For miRNA-140-3p, this procedure revealed a network associated with cell cycle, connective tissue development, and cellular function and maintenance. The central regulators in this pathway are <italic>p53, NF-KB</italic>, and <italic>HDAC1</italic>.The top cellular functions of both miRNA-29 and miRNA 140-3p gene targets identify cellular assembly and organization and cell-to-cell signaling and involve <italic>IGF-1</italic>. Additional functions identified include cell death, cell growth and proliferation, and cell morphological processes.</p>
</sec>
</sec>
<sec id="section25-0194599812442490" sec-type="discussion">
<title>Discussion</title>
<p>Dysregulation of miRNA has been shown in various types of cancer.<sup><xref ref-type="bibr" rid="bibr18-0194599812442490">18</xref><xref ref-type="bibr" rid="bibr19-0194599812442490"/>-<xref ref-type="bibr" rid="bibr20-0194599812442490">20</xref></sup> Many cellular mechanisms appear to be under the control of miRNA in both normal and cancerous tissue.<sup><xref ref-type="bibr" rid="bibr21-0194599812442490">21</xref></sup> Although miRNA studies are increasing for all types of cancer,<sup><xref ref-type="bibr" rid="bibr22-0194599812442490">22</xref><xref ref-type="bibr" rid="bibr23-0194599812442490"/>-<xref ref-type="bibr" rid="bibr24-0194599812442490">24</xref></sup> we are now starting to learn more about the importance of miRNAs in head and neck cancer.<sup><xref ref-type="bibr" rid="bibr25-0194599812442490">25</xref><xref ref-type="bibr" rid="bibr26-0194599812442490"/>-<xref ref-type="bibr" rid="bibr27-0194599812442490">27</xref></sup> Despite these advances, there is a paucity of published information regarding differential miRNA expression in metastatic OSCC and the functional impact of these differentially expressed miRNAs on their target genes. Our study is unique in several important ways. First, it uses integrative genomics in metastatic OSCC to identify miRNA dysregulation that is associated with DNA copy number aberrations and to understand the impact that miRNAs might be having on the expression of their target genes. Second, besides considering the association between the DNA copy number of each miRNA and miRNA dysregulation, when assessing the association between miRNA levels and their target genes, we also considered the impact of a target gene’s DNA copy number on its expression. This is important because we have shown a strong positive correlation between DNA copy number aberrations and the expression levels of the corresponding encoded genes.<sup><xref ref-type="bibr" rid="bibr4-0194599812442490">4</xref></sup> Thus, we believe this to be essential when determining the true impact of miRNA expression on its gene targets. Third, we focused on metastasis by establishing a comparison between laser-dissected tumor cells from nonmetastatic primary carcinomas and tumor cells metastatic to lymph nodes, rather than a pair-wise comparison between tumor cells from primary OSCC known to have metastatic behavior and the metastatic tumor cells from lymph nodes. This distinction is important, because there is evidence that prior to metastasis, the carcinoma in the primary site has already developed tumor cells with genetic changes associated with metastatic potential, as we and others have shown.<sup><xref ref-type="bibr" rid="bibr28-0194599812442490">28</xref><xref ref-type="bibr" rid="bibr29-0194599812442490"/>-<xref ref-type="bibr" rid="bibr30-0194599812442490">30</xref></sup> Our study aimed to detect miRNA differences and differences in target gene regulation that could provide additional information relevant to the metastatic tumor phenotype, which might have been lost if our primary tumor samples were from patients with known metastases at the time of collection.</p>
<p>It is challenging to evaluate the overall impact of dysregulated miRNA in metastasis because of the complexity of the miRNA/target gene interaction. Each individual miRNA can bind to many target genes with varying degrees of specificity, and, conversely, each gene can be targeted by multiple miRNAs. In fact, of the 155 miRNAs expressed in our samples, we discovered that the overall number of genes possibly under miRNA control reached 47,385. Each of these miRNAs could potentially bind between 20 and 1000 target genes. We only accounted for the top 3 gene candidates to which a given miRNA could bind in order to keep the multiple comparisons penalties low. This limitation may explain why the genome-wide association between our expressed miRNAs and the expression of their top gene targets did not reveal a general preponderance for miRNAs to have a negative impact on the transcriptome. Other limitations include small sample size, the fact that we combined oral cavity and oropharyngeal cancers, the absence of information regarding the patient’s HPV status in the analysis, and the lack of assessment of protein expression. In addition, although our primary tumor samples were from patients without known metastases, the follow-up interval between our collection dates and our investigation may not be long enough to determine whether some of the tumors might have spread beyond the primary site. This might have diluted the results of our study. However, none of the patients with nonmetastatic disease had nodal recurrences during their follow-up period. In addition, the metastatic tumor cells used in our study comprised carcinoma cells dissected from lymph nodes; our results may not be applicable to squamous carcinoma cells that have metastasized to other sites, such as lung or bone. Further studies with larger sample sizes, tumor cells metastatic to other sites, and longer follow-up intervals are needed to determine the impact of these factors relating to miRNAs in OSCC and their role in tumor metastasis.</p>
<p>Our integrated results indicate that the expression of hsa-miR-29a, hsa-miR-29c, and hsa-miR-140-3p is related to their DNA copy number, is differentially expressed in metastatic versus nonmetastatic OSCC and that their expression has a significant impact on the expression of their target genes. These 3 miRNAs may play a role in the development of metastatic behavior of tumor cells by directly down-regulating expression of their specific target genes. It should also be noted that miR-29a has been used for early detection of colorectal liver metastasis<sup><xref ref-type="bibr" rid="bibr31-0194599812442490">31</xref></sup> and has been associated with metastasis and poor prognosis in clear cell renal cell carcinoma,<sup><xref ref-type="bibr" rid="bibr32-0194599812442490">32</xref></sup> highlighting the importance of this miRNA in metastatic pathways. Overexpression of miR-29c is being studied as a potential biomarker in diffuse large B-cell lymphoma<sup><xref ref-type="bibr" rid="bibr33-0194599812442490">33</xref></sup> as well as in nonsmall cell lung cancer.<sup><xref ref-type="bibr" rid="bibr34-0194599812442490">34</xref></sup> Additionally, miR-140-3p has been shown to be correlated with the occurrence of LOH at 16q22.1-q23.1 in multiple myeloma.<sup><xref ref-type="bibr" rid="bibr35-0194599812442490">35</xref></sup> Our pathway analysis found that these 3 miRNAs were associated with several relevant cancer-related pathways and networks, including cell cycle, cell-to-cell signaling, and cell morphological processes. Together these results suggest that miR-29a/c and miR-140-3p may play a role in OSCC metastasis to lymph nodes, and this observation warrants further investigation as well as investigation in other sites of metastasis.</p>
</sec>
<sec id="section26-0194599812442490">
<title>Author Contributions</title>
<p><bold>Nicholas A. Serrano</bold>, design, acquisition of data, analysis and interpretation of data, drafting the article; <bold>Chang Xu</bold>, design, acquisition of data, analysis and interpretation of data; <bold>Yan Liu</bold>, analysis and interpretation of data; <bold>Pei Wang</bold>, analysis and interpretation of data; <bold>Wenhong Fan</bold>, analysis and interpretation of data; <bold>Melissa P. Upton</bold>, design and acquisition of data; <bold>John R. Houck</bold>, design and acquisition of data; <bold>Pawadee Lohavanichbutr</bold>, design and acquisition of data; <bold>Michael Kao</bold>, design, acquisition of data, analysis and interpretation of data, drafting the article; <bold>Lue Ping Zhao</bold>, analysis and interpretation of data; <bold>Stephen M. Schwartz</bold>, design and acquisition of data, analysis and interpretation; <bold>Chu Chen</bold>, design and acquisition of data, analysis and interpretation; <bold>Eduardo Méndez</bold>, principal investigator; design, acquisition of data, analysis and interpretation of data, drafting the article.</p>
</sec>
<sec id="section27-0194599812442490">
<title>Disclosures</title>
<p><bold>Competing interests:</bold> Eduardo Méndez, consultant/proctor for robotic surgery, for Intuitive Surgical, Inc.</p>
<p><bold>Sponsorships:</bold> None.</p>
<p><bold>Funding source:</bold> This work was supported in part by grants 5KL2RR025015-03 from National Center for Research Resources, National Institutes of Health (NIH); Amos Medical Faculty Development Program Award from the Robert Wood Johnson Foundation; Early Physician-Scientist Career Development Award from the Howard Hughes Medical Institute; 5T32DC000018-27 from the NIH, Department of Health and Human Services Public Health Service Ruth L. Kirschstein National Research Service Award; NIH RO1CA095419; funds from the Fred Hutchinson Cancer Research center; and center funds from the Department of Otolaryngology–Head and Neck Surgery, University of Washington; and by resources from and use of facilities at the VA Puget Sound Health Care System, Fred Hutchinson Cancer Research Center, University of Washington Medical Center and Harborview Medical Center, Seattle, Washington.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="presented-at">
<p>Sponsorships or competing interests that may be relevant to content are disclosed at the end of this article.</p>
<p>This article was presented at the 2011 AAO-HNSF Annual Meeting &amp; OTO EXPO; September 11-14, 2011; San Francisco, California.</p>
</fn>
<fn fn-type="supplementary-material">
<p>Additional supporting information may be found at <ext-link ext-link-type="uri" xlink:href="http://oto.sagepub.com/content/by/supplemental-data">http://oto.sagepub.com/content/by/supplemental-data</ext-link></p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0194599812442490">
<label>1.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Jemal</surname><given-names>A</given-names></name>
<name><surname>Murray</surname><given-names>T</given-names></name>
<name><surname>Ward</surname><given-names>E</given-names></name>
<etal/>
</person-group>. <article-title>Cancer statistics, 2005</article-title>. <source>CA Cancer J Clin</source>. <year>2005</year>;<volume>55</volume>:<fpage>10</fpage>-<lpage>30</lpage>.</citation>
</ref>
<ref id="bibr2-0194599812442490">
<label>2.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Forastiere</surname><given-names>AA</given-names></name>
<name><surname>Trotti</surname><given-names>A</given-names></name>
<name><surname>Pfister</surname><given-names>DG</given-names></name>
<name><surname>Grandis</surname><given-names>JR</given-names></name>
</person-group>. <article-title>Head and neck cancer: recent advances and new standards of care</article-title>. <source>J Clin Oncol</source>. <year>2006</year>;<volume>24</volume>:<fpage>2603</fpage>-<lpage>2605</lpage>.</citation>
</ref>
<ref id="bibr3-0194599812442490">
<label>3.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Imre</surname><given-names>K</given-names></name>
<name><surname>Pinar</surname><given-names>E</given-names></name>
<name><surname>Oncel</surname><given-names>S</given-names></name>
<name><surname>Calli</surname><given-names>C</given-names></name>
<name><surname>Tatar</surname><given-names>B</given-names></name>
</person-group>. <article-title>Predictors of extracapsular spread in lymph node metastasis</article-title>. <source>Eur Arch Otorhinolaryngol</source>. <year>2008</year>;<volume>265</volume>:<fpage>337</fpage>-<lpage>339</lpage>.</citation>
</ref>
<ref id="bibr4-0194599812442490">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Xu</surname><given-names>C</given-names></name>
<name><surname>Liu</surname><given-names>Y</given-names></name>
<name><surname>Wang</surname><given-names>P</given-names></name>
<etal/>
</person-group>. <article-title>Integrative analysis of DNA copy number and gene expression in metastatic oral squamous cell carcinoma identifies genes associated with poor survival</article-title>. <source>Mol Cancer</source>. <year>2010</year>;<volume>9</volume>:<fpage>143</fpage>.</citation>
</ref>
<ref id="bibr5-0194599812442490">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wong</surname><given-names>TS</given-names></name>
<name><surname>Liu</surname><given-names>XB</given-names></name>
<name><surname>Wong</surname><given-names>BY</given-names></name>
<name><surname>Ng</surname><given-names>RW</given-names></name>
<name><surname>Yuen</surname><given-names>AP</given-names></name>
<name><surname>Wei</surname><given-names>WI</given-names></name>
</person-group>. <article-title>Mature miR-184 as potential oncogenic microRNA of squamous cell carcinoma of tongue</article-title>. <source>Clin Cancer Res</source>. <year>2008</year>;<volume>14</volume>:<fpage>2588</fpage>-<lpage>2592</lpage>.</citation>
</ref>
<ref id="bibr6-0194599812442490">
<label>6.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kozaki</surname><given-names>K</given-names></name>
<name><surname>Imoto</surname><given-names>I</given-names></name>
<name><surname>Mogi</surname><given-names>S</given-names></name>
<name><surname>Omura</surname><given-names>K</given-names></name>
<name><surname>Inazawa</surname><given-names>J</given-names></name>
</person-group>. <article-title>Exploration of tumor-suppressive microRNAs silenced by DNA hypermethylation in oral cancer</article-title>. <source>Cancer Res</source>. <year>2008</year>;<volume>68</volume>:<fpage>2094</fpage>-<lpage>2105</lpage>.</citation>
</ref>
<ref id="bibr7-0194599812442490">
<label>7.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tang</surname><given-names>G</given-names></name>
<name><surname>Reinhart</surname><given-names>BJ</given-names></name>
<name><surname>Bartel</surname><given-names>DP</given-names></name>
<name><surname>Zanmore</surname><given-names>PD</given-names></name>
</person-group>. <article-title>A biochemical framework for RNA silencing in plants</article-title>. <source>Genes Dev</source>. <year>2003</year>;<volume>17</volume>:<fpage>49</fpage>-<lpage>63</lpage>.</citation>
</ref>
<ref id="bibr8-0194599812442490">
<label>8.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pasquinelli</surname><given-names>AE</given-names></name>
<name><surname>Ruvkun</surname><given-names>G</given-names></name>
</person-group>. <article-title>Control of developmental timing of microRNAs and their targets</article-title>. <source>Annu Rev Cell Dev Biol</source>. <year>2002</year>;<volume>18</volume>:<fpage>495</fpage>-<lpage>513</lpage>.</citation>
</ref>
<ref id="bibr9-0194599812442490">
<label>9.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Yetka</surname><given-names>S</given-names></name>
<name><surname>Shih</surname><given-names>IH</given-names></name>
<name><surname>Bartel</surname><given-names>DP</given-names></name>
</person-group>. <article-title>MicroRNA-directed cleavage of HOXB8 mRNA</article-title>. <source>Science</source>. <year>2004</year>;<volume>304</volume>:<fpage>594</fpage>-<lpage>596</lpage>.</citation>
</ref>
<ref id="bibr10-0194599812442490">
<label>10.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Xu</surname><given-names>C</given-names></name>
<name><surname>Houck</surname><given-names>JR</given-names></name>
<name><surname>Fan</surname><given-names>W</given-names></name>
<etal/>
</person-group>. <article-title>Simultaneous isolation of DNA and RNA from the same cell population obtained by laser capture microdissection for genome and transcriptome profiling</article-title>. <source>J Mol Diagn</source>. <year>2008</year>;<volume>10</volume>:<fpage>129</fpage>-<lpage>134</lpage>.</citation>
</ref>
<ref id="bibr11-0194599812442490">
<label>11.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hui</surname><given-names>AB</given-names></name>
<name><surname>Lenarduzzi</surname><given-names>M</given-names></name>
<name><surname>Krushel</surname><given-names>T</given-names></name>
<etal/>
</person-group>. <article-title>Comprehensive MicroRNA profiling for head and neck squamous cell carcinomas</article-title>. <source>Clin Cancer Res</source>. <year>2010</year>;<volume>16</volume>:<fpage>1129</fpage>-<lpage>1139</lpage>.</citation>
</ref>
<ref id="bibr12-0194599812442490">
<label>12.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pfaffl</surname><given-names>M</given-names></name>
</person-group>. <article-title>A new mathematical model for relative quantification in realtime RT-PCR</article-title>. <source>Nucleic Acids Res</source>. <year>2001</year>;<volume>29</volume>:<fpage>e45</fpage>.</citation>
</ref>
<ref id="bibr13-0194599812442490">
<label>13.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Benjamini</surname><given-names>Y</given-names></name>
<name><surname>Hochberg</surname><given-names>Y</given-names></name>
</person-group>. <article-title>Controlling the false discovery rate: a practical and powerful approach to multiple testing</article-title>. <source>J R Stat Soc Ser B</source>. <year>1995</year>;<volume>57</volume>:289<source>-</source>300.</citation>
</ref>
<ref id="bibr14-0194599812442490">
<label>14.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kozomara</surname><given-names>A</given-names></name>
<name><surname>Griffiths-Jones</surname><given-names>S</given-names></name>
</person-group>. <article-title>miRBase: integrating microRNA annotation and deep-sequencing data</article-title>. <source>Nucleic Acids Research</source>. <year>2011</year>;<volume>39</volume>(<issue>Database Issue</issue>):<fpage>D152</fpage>-<lpage>D157</lpage>.</citation>
</ref>
<ref id="bibr15-0194599812442490">
<label>15.</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Griffiths-Jones</surname><given-names>S</given-names></name>
<name><surname>Saini</surname><given-names>HK</given-names></name>
<name><surname>van Dongen</surname><given-names>S</given-names></name>
<name><surname>Enright</surname><given-names>AJ</given-names></name>
</person-group>. <article-title>miRBase: tools for microRNA genomics</article-title>. <source>Nucleic Acids Research</source>. <year>2008</year>;<volume>36</volume>(<issue>Database Issue</issue>):<fpage>D154</fpage>-<lpage>D158</lpage>.</citation>
</ref>
<ref id="bibr16-0194599812442490">
<label>16.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Griffiths-Jones</surname><given-names>S</given-names></name>
<name><surname>Grocock</surname><given-names>RJ</given-names></name>
<name><surname>van Dongen</surname><given-names>S</given-names></name>
<name><surname>Bateman</surname><given-names>A</given-names></name>
<name><surname>Enright</surname><given-names>AJ</given-names></name>
</person-group>. <article-title>miRBase: microRNA sequences, targets and gene nomenclature</article-title>. <source>Nucleic Acids Research</source>. <year>2006</year>;<volume>34</volume>(<issue>Database Issue</issue>):<fpage>D140</fpage>-<lpage>D144</lpage>.</citation>
</ref>
<ref id="bibr17-0194599812442490">
<label>17.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Griffiths-Jones</surname><given-names>S</given-names></name>
</person-group>. <article-title>The microRNA Registry</article-title>. <source>Nucleic Acids Research</source>. <year>2004</year>;<volume>32</volume>(<issue>Database Issue</issue>):<fpage>D109</fpage>-<lpage>D111</lpage>.</citation>
</ref>
<ref id="bibr18-0194599812442490">
<label>18.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tong</surname><given-names>AW</given-names></name>
<name><surname>Fulgham</surname><given-names>P</given-names></name>
<name><surname>Jay</surname><given-names>C</given-names></name>
<etal/>
</person-group>. <article-title>MicroRNA profile analysis of human prostate cancers</article-title>. <source>Cancer Gene Ther</source>. <year>2009</year>;<volume>16</volume>:<fpage>206</fpage>-<lpage>216</lpage>.</citation>
</ref>
<ref id="bibr19-0194599812442490">
<label>19.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bandrés</surname><given-names>E</given-names></name>
<name><surname>Cubedo</surname><given-names>E</given-names></name>
<name><surname>Agirre</surname><given-names>X</given-names></name>
<etal/>
</person-group>. <article-title>Identification by real-time PCR of 13 mature microRNAs differentially expressed in colorectal cancer and non-tumoral tissues</article-title>. <source>Mol Cancer</source>. <year>2006</year>;<volume>5</volume>:<fpage>29</fpage>.</citation>
</ref>
<ref id="bibr20-0194599812442490">
<label>20.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gottardo</surname><given-names>F</given-names></name>
<name><surname>Liu</surname><given-names>CG</given-names></name>
<name><surname>Ferracin</surname><given-names>M</given-names></name>
<etal/>
</person-group>. <article-title>Micro-RNA profiling in kidney and bladder cancers</article-title>. <source>Urol Oncol</source>. <year>2007</year>;<volume>25</volume>:<fpage>387</fpage>-<lpage>392</lpage>.</citation>
</ref>
<ref id="bibr21-0194599812442490">
<label>21.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ha</surname><given-names>TY</given-names></name>
</person-group>. <article-title>MicroRNAs in human diseases: from cancer to cardiovascular disease</article-title>. <source>Immune Netw</source>. <year>2011</year>;<volume>11</volume>:<fpage>135</fpage>-<lpage>154</lpage>.</citation>
</ref>
<ref id="bibr22-0194599812442490">
<label>22.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rask</surname><given-names>L</given-names></name>
<name><surname>Balslev</surname><given-names>E</given-names></name>
<name><surname>J⊘rgensen</surname><given-names>S</given-names></name>
<etal/>
</person-group>. <article-title>High expression of miR-21 in tumor stroma correlates with increased cancer cell proliferation in human breast cancer</article-title>. <source>APMIS</source>. <year>2011</year>;<volume>119</volume>:<fpage>663</fpage>-<lpage>673</lpage>.</citation>
</ref>
<ref id="bibr23-0194599812442490">
<label>23.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Yao</surname><given-names>T</given-names></name>
<name><surname>Lin</surname><given-names>Z</given-names></name>
</person-group>. <article-title>MiR-21 is involved in cervical squamous cell tumorigenesis and regulates CCL20</article-title>. <source>Biochim Biophys Acta</source>. <year>2012</year>;<volume>1822</volume>:<fpage>248</fpage>-<lpage>260</lpage>.</citation>
</ref>
<ref id="bibr24-0194599812442490">
<label>24.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Yang</surname><given-names>CH</given-names></name>
<name><surname>Yue</surname><given-names>J</given-names></name>
<name><surname>Pfeffer</surname><given-names>SR</given-names></name>
<name><surname>Handorf</surname><given-names>CR</given-names></name>
<name><surname>Pfeffer</surname><given-names>LM</given-names></name>
</person-group>. <article-title>MicroRNA-21 regulates the metastatic behavior of B16 melanoma cells</article-title>. <source>J Biol Chem</source>. <year>2011</year>;<volume>286</volume>:<fpage>39172</fpage>-<lpage>39178</lpage>.</citation>
</ref>
<ref id="bibr25-0194599812442490">
<label>25.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Chang</surname><given-names>SS</given-names></name>
<name><surname>Jiang</surname><given-names>WW</given-names></name>
<name><surname>Smith</surname><given-names>I</given-names></name>
<etal/>
</person-group>. <article-title>MicroRNA alterations in head and neck squamous cell carcinoma</article-title>. <source>Int J Cancer</source>. <year>2008</year>;<volume>123</volume>:<fpage>2791</fpage>-<lpage>2797</lpage>.</citation>
</ref>
<ref id="bibr26-0194599812442490">
<label>26.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lajer</surname><given-names>CB</given-names></name>
<name><surname>Nielsen</surname><given-names>FC</given-names></name>
<name><surname>Friis-Hansen</surname><given-names>L</given-names></name>
<etal/>
</person-group>. <article-title>Different miRNA signatures of oral and pharyngeal squamous cell carcinomas: a prospective translational study</article-title>. <source>Br J Cancer</source>. <year>2011</year>;<volume>104</volume>:<fpage>830</fpage>-<lpage>840</lpage>.</citation>
</ref>
<ref id="bibr27-0194599812442490">
<label>27.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ramdas</surname><given-names>L</given-names></name>
<name><surname>Giri</surname><given-names>U</given-names></name>
<name><surname>Ashorn</surname><given-names>CL</given-names></name>
<etal/>
</person-group>. <article-title>miRNA expression profiles in head and neck squamous cell carcinoma and adjacent normal tissue</article-title>. <source>Head Neck</source>. <year>2009</year>;<volume>31</volume>:<fpage>642</fpage>-<lpage>654</lpage>.</citation>
</ref>
<ref id="bibr28-0194599812442490">
<label>28.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Méndez</surname><given-names>E</given-names></name>
<name><surname>Fan</surname><given-names>W</given-names></name>
<name><surname>Choi</surname><given-names>P</given-names></name>
<etal/>
</person-group>. <article-title>Tumor-specific genetic expression profile of metastatic oral squamous cell carcinoma</article-title>. <source>Head Neck</source>. <year>2007</year>;<volume>29</volume>:<fpage>803</fpage>-<lpage>814</lpage>.</citation>
</ref>
<ref id="bibr29-0194599812442490">
<label>29.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>van’t Veer</surname><given-names>LJ</given-names></name>
<name><surname>Dai</surname><given-names>H</given-names></name>
<name><surname>van</surname><given-names>de</given-names></name>
<name><surname>Vijver</surname><given-names>MJ</given-names></name>
<etal/>
</person-group>. <article-title>Gene expression profiling predicts clinical outcome of breast cancer</article-title>. <source>Nature</source>. <year>2002</year>;<volume>415</volume>:<fpage>530</fpage>-<lpage>536</lpage>.</citation>
</ref>
<ref id="bibr30-0194599812442490">
<label>30.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kang</surname><given-names>Y</given-names></name>
<name><surname>Siegel</surname><given-names>PM</given-names></name>
<name><surname>Shu</surname><given-names>W</given-names></name>
<etal/>
</person-group>. <article-title>A multigenic program mediating breast cancer metastasis to bone</article-title>. <source>Cancer Cell</source>. <year>2003</year>;<volume>3</volume>:<fpage>537</fpage>-<lpage>549</lpage>.</citation>
</ref>
<ref id="bibr31-0194599812442490">
<label>31.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wang</surname><given-names>LG</given-names></name>
<name><surname>Gu</surname><given-names>J</given-names></name>
</person-group>. <article-title>Serum microRNA-29a is a promising novel marker for early detection of colorectal liver metastasis</article-title>. <source>Cancer Epidemiol</source>. <year>2012</year>;<volume>36</volume>:<fpage>e61</fpage>-<lpage>e67</lpage>.</citation>
</ref>
<ref id="bibr32-0194599812442490">
<label>32.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Heinzelmann</surname><given-names>J</given-names></name>
<name><surname>Henning</surname><given-names>B</given-names></name>
<name><surname>Sanjmyatav</surname><given-names>J</given-names></name>
<etal/>
</person-group>. <article-title>Specific miRNA signatures are associated with metastasis and poor prognosis in clear cell renal cell carcinoma</article-title>. <source>World J Urol</source>. <year>2011</year>;<volume>29</volume>:<fpage>367</fpage>-<lpage>373</lpage>.</citation>
</ref>
<ref id="bibr33-0194599812442490">
<label>33.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Fang</surname><given-names>C</given-names></name>
<name><surname>Zhu</surname><given-names>DX</given-names></name>
<name><surname>Dong</surname><given-names>HJ</given-names></name>
<etal/>
</person-group>. <article-title>Serum microRNAs are promising novel biomarkers for diffuse large B cell lymphoma</article-title> [<comment>published online ahead of print October 11, 2011</comment>]. <source>Ann Hematol</source>.</citation>
</ref>
<ref id="bibr34-0194599812442490">
<label>34.</label>
<citation citation-type="book">
<person-group person-group-type="editor">
<name><surname>Heegaard</surname><given-names>NH</given-names></name>
<name><surname>Schetter</surname><given-names>AJ</given-names></name>
<name><surname>Welsh</surname><given-names>JA</given-names></name>
<name><surname>Yoneda</surname><given-names>M</given-names></name>
<name><surname>Bowman</surname><given-names>ED</given-names></name>
<name><surname>Harris</surname><given-names>CC</given-names></name>
</person-group>. <article-title>Circulating microRNA expression profiles in early stage non-small cell lung cancer</article-title>. <source>Int J Cancer</source>. <year>2012</year>;<volume>130</volume>:<fpage>1378</fpage>-<lpage>1386</lpage>.</citation>
</ref>
<ref id="bibr35-0194599812442490">
<label>35.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lionetti</surname><given-names>M</given-names></name>
<name><surname>Biasiolo</surname><given-names>M</given-names></name>
<name><surname>Agnelli</surname><given-names>L</given-names></name>
<etal/>
</person-group>. <article-title>Identification of microRNA expression patterns and definition of a microRNA/mRNA regulatory network in distinct molecular groups of multiple myeloma</article-title>. <source>Blood</source>. <year>2009</year>;<volume>114</volume>:<fpage>e20</fpage>-<lpage>e26</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>